EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
- PMID: 35697871
- DOI: 10.1007/s00259-022-05864-z
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
References
-
- Fanti S, Briganti A, Emmett L, et al. EAU-EANM consensus statements on the role of PSMA PET/CT in patients with prostate cancer and in respect to radioligand therapy ([177Lu]Lu-PSMA). Eur Urol Oncol. 2022; In press.
-
- Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Published 2022. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-E... . Accessed 4 Apr 2022.
-
- Fendler WP, Eiber M, Beheshti M, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24. - DOI
-
- Gillessen S, Armstrong A, Attard G, et al. Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;18:S0302–2838(22) 01807-3.
-
- Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):469–76. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous